AEON Biopharma, Inc. (NYSEAM: AEON)
Health Care · Biotechnology · US
$0.22
-21.52% today · -63.6% 1Y
AEON Biopharma, Inc. (NYSEAM: AEON) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.24M and employs 8 people.
Over the last twelve months the share price has lost 63.6%, trading between 0.22 and 1.45.
Tweenvest scores AEON Biopharma, Inc. across four factors: quality 16/100. Its strongest factor is quality.
AEON price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.24M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.89
- Dividend yield
- —
- Beta (5Y)
- 0.64
- 52-week high
- $1.45
- 52-week low
- $0.22
- Avg volume (3M)
- —
- Shares outstanding
- 26.31M
- Employees
- 8
- Next earnings
- —
About AEON Biopharma, Inc.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
- ISIN
- US00791X2099
- Listed since
- Jul 24, 2023
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.99 | +0.62% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.84 | -2.51% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.